Aralen (Chloroquine) is an anti-malaria drug. It also has an immunosuppressive and anti-inflammatory effect. It causes the death of asexual erythrocyte forms of all types of plasmodia. It has a gametocidal effect, with the exception of Plasmodium falciparum (exhibits an anti-gametocidal effect).
- Malaria (prevention and treatment of all types);
- Extraintestinal amoebiasis;
- Amoebic liver abscess;
- The systemic lupus erythematosus (chronic and subacute forms);
- Rheumatoid arthritis;
- Oral administration. for the prevention of malaria – 0.5 g in the first week 2 times, then 1 time always on the same day of the week.
- The treatment of malaria is carried out according to the following scheme: 1 day once 1 g, after 6-8 hours – 0.5 g, on days 2 and 3 of treatment – 0.75 g daily in one dose.
- Amoebiasis, 0.5 g 3 times/day for 7 days, then 0.25 g 3 times/day for another 7 days, then 0.75 g 2 times a week for 2-6 months.
- Rheumatoid arthritis – 0.5 g 2 times/day for 7 days, then – 0.5 g daily for 12 months.
- Systemic lupus erythematosus – daily, 0.25-0.5 g.
- Photodermatosis, 0.25 g daily for a week, then 0.5-0.75 g weekly.
- Digestive system: nausea, vomiting, gastralgia.
- Nervous system: dizziness, headache, sleep disturbances, psychoses, epileptic seizures.
- Cardiovascular system: myocardial damage with changes in the ECG, decreased blood pressure.
- Sensory organs: with prolonged use – clouding of the cornea, damage to the retina, impaired vision, ringing in the ears.
- Allergic reactions: dermatitis, photosensitivity.
- Other: myalgia, leukopenia, discoloration of the skin and hair.
- Liver failure;
- Renal failure;
- Inhibition of bone marrow hematopoiesis;
- Severe rhythm disturbances;
- Psoriatic arthritis;
Aralen (Chloroquine) is taken with caution in patients with glucose-6-phosphate dehydrogenase deficiency, retinopathy, epilepsy.
Pregnancy and lactation
Aralen is contraindicated during pregnancy and lactation.
Symptoms: vomiting, impaired consciousness, impaired vision, convulsions, collapse, respiratory depression ending to death.
Treatment: vomiting, gastric lavage, ingestion of activated charcoal in a dose 5 times the expected dose of chloroquine; peritoneal dialysis, plasmapheresis.
- Co-administration with phenylbutazone, gold preparations, penicillamine, cytostatics, levamisole increases the likelihood of bone marrow aplasia and skin lesions.
- Antacids disrupt absorption, cimetidine increases the drug concentration in the blood.
- The combination with other antimalarial drugs may be accompanied by an antagonistic effect.
- When combined with glucocorticosteroids, the risk of developing myopathy and cardiomyopathy increases, with MAO inhibitors, the risk of developing neurotoxicity increases, with ethanol – hepatotoxicity, with cardiac glycosides – glycosidic intoxication increases.